Form 4: Cabaletta Bio Director Henriques Receives Repriced Stock Options

Richard C. Henriques Jr., a director at Cabaletta Bio, Inc., received repriced stock options on May 19, 2025, as part of an option repricing approved by the board.

Summary

• Richard C. Henriques Jr., a director at Cabaletta Bio, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 19, 2025, Henriques received repriced stock options with an exercise price of $1.92 per share, reflecting the fair market value on the repricing date.
• The repricing was approved by the Issuer's board of directors on May 15, 2025.
• The repriced options will revert to their original exercise price if exercised during a one-year retention period, unless a Sale Event or termination of service due to death or disability occurs.
• Henriques also disposed of existing stock options with exercise prices of $6.30, $11.00, $11.18 and $10.01.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports a transaction. The repricing could be seen as positive for retention but potentially negative if the original options were underwater due to poor performance.

Positives

• The option repricing aligns the director's incentives with the current market value of the company's stock.
• The retention period encourages continued service by the director.

Risks

• The repricing could be viewed negatively by shareholders if the original options were underwater due to poor company performance.

Future Outlook

The document does not contain any specific forward-looking statements beyond the terms of the option repricing and vesting schedule.

Industry Context

Option repricing is a common practice in the biotech industry to retain key personnel when a company's stock price has declined. It aims to re-incentivize employees and align their interests with shareholders.

Comparison to Industry Standards

• Option repricing is a fairly common practice, especially in volatile sectors like biotechnology.
• Companies like Amgen and Biogen have used similar strategies in the past to retain key employees during periods of stock price decline.
• The one-year retention period is a standard condition to ensure continued service.

Stakeholder Impact

• Shareholders may view the repricing as a necessary measure to retain a key director, or they may be concerned about the dilution effect of additional options.
• The director benefits from the repricing, as it increases the likelihood that the options will have value.

Key Dates

Keywords

stock options, Form 4, Cabaletta Bio, Henriques, repricing, director, beneficial ownership